

Note: Ordered tests may not be performed if appropriate diagnostic or pathologic codes are not submitted. Most cytogenetic, flow cytometry, FISH and molecular tests require pre-authorization obtained by ordering clinician for coverage. If there is no pre-authorization, an ABN form may be required to perform testing.
Clinical Findings or History ICD10 codes (must have appropriate codes for testing): $\qquad$ —

Working diagnoses/concerns

## Evaluation requested

_ Complete Bone marrow and peripheral blood evaluation (including flow
cytometry, cytogenetics, FISH and molecular studies if indicated per pathologist findings and clinical concern)
__ Hemepath Consult (CBC and Pathologist report of findings)
_ HemePath Consult with Client Submitted CBC
Tissue or fluid morphologic assessment: Type $\qquad$
$\square$ Microbiology Cultures -
$\square$ Anaerobic $\square$ AerobicFungus $\square$ AFB
(Note: Molecular testing recommended for viral infection evaluation, not viral cultures)

Flow Cytometry
Screening panel (blasts, lymphocytes, myeloid cells (expand if needed)
T and B cell disorder/lymphoma panel
(expand if needed)
Plasma cell neoplasm/myeloma
Acute leukemia panel
PNH Panel

## Cytogenetic/molecular testing

__ Chromosomal karyotype analysis (blood, bone marrow)

## Myeloid Neoplasms/myeloproliferative/AML

_ NGS Panel, myeloid disorders
__ FISH: PML/RARA, $\mathrm{t}(15 ; 17)$ for Acute Promyelocytic Leukemia
__ FISH: 11q23 (MLL/KMT2A) Rearrangement
_ FISH: AML1/ETO, t $(8,21)$
__ FISH: CBFB, Inv(16), t(16;16)
_ FISH: BCR/ABL t(9;22)
_ FISH: Myeloid Disorder Panel (chromosomes 5, 7, 8, 20)
_ PCR: PML/RARA t(15;17), Quantitative
_ PCR: CEBPA Mutation
__ PCR: FLT3 Mutations (ITD)
__ PCR:RUNX1 Mutation
_ PCR:KIT Mutation
__ PCR: NPM1 (Exon 12) Mutation
_ PCR: IDH1/IDH2 Mutation
_ PCR:TP53 Mutation
_ PCR: JAK2 V617F Mutation
__ MPN Molecular Panel including JAK2 exon 12, MPL, CALR
(only performed if negative for JAK2 V617F)
FISH: CHIC2 deletion (FIP1L1-PDGFRA) 4q12 PDGFRB and FLP1 (rearrangements will be detected by chromosomal karyotypic analysis

Acute lymphoblastic leukemia/ALL/Lymphoma/LPDs/Plasma cell neoplasms FISH: BCR/ABL, $\mathrm{t}(9 ; 22)$
__ FISH: BCR/ABL with reflex testing for BCR-ABL-like
FISH: 11q23 (MLL/KMT2A) Rearrangement
FISH: t(12:21) ETV/RUNX1
PCR: BCR/ABL $t(9 ; 22)$, quantitative
Lymphoma, LPDs, and Plasma cell neoplasm
FISH: IGH/MAF fusion; TP53/17 cep loci: CKS1/CDKN2C loci
__ FISH: B-Cell CLL Panel [+12, del13q14.3, del 13q34, del17p13.1, del11q22.3]
__ FISH: Mantle Cell Lymphoma CCND1/IGH t(11;14)
__ FISH: Follicular Lymphoma IGH/BCL2 t(14;18)
__ FISH: Burkitt Lymphoma, MYC/IGH t(8;14)
__ FISH: MYC, 8q24 Rearrangement
__ FISH: MYC w/ reflex to BCL2 (18q21), and BCL6 (3q27)
__ PCR: Mantle Cell Lymphoma, CCND1/IGH t(11;14)
__ PCR: B-Cell (IgH, Heavy Chain) Gene Rearrangement
__ PCR: T-Cell Receptor (TCR) Gene Rearrangement

## Solid Tumor, Molecular Testing

__ Lung Panel NGS
_ Melanoma Panel NGS
_ Solid Tumor Panel NGS
_ Colon Panel NGS
__ PDL-1 (22C3 IHC with Tumor Proportion Score (TPS) Keytruda
_ PDL-1 (22C3 IHC with Combined Positive Score (CPS) Keytruda
__PDL-1 (28-8 pharmDX by IHC w/interp Opdivo)
__ PDL-1 (SP263 IHC with Tumor Proportion Score (TPS) Tecentriq and cemiplimab-rwlc Libtayo
__ MMR by IHC

